Clinical Trial Update: A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase I first-in-human study of GB268, a PD-1/CTLA-4/VEGF trispecific antibody, in patients with advanced solid tumors; trial status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• GB268 (PD-1/CTLA-4/VEGF trispecific antibody)

Snippet

Sponsor: Genor Biopharma Co., Ltd. | Conditions: Solid Tumor Cancer | Phase 1 | Status: NOT_YET_RECRUITING